Vir Biotechnology, Inc. Common Stock (VIR) Stock Price

VIRStock

$10.71+116.38%52W

Market Cap$1.81B

P/E—

PEG Ratio—

Div yield—

Beta1.60

VIR Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)15.32%

Price vs S&P 500 (4W)8.93%

VGM Score71.98

Book Value / Share (Quarterly)$5.81

P/TBV (Annual)1.11x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-65.12%

Cash Flow / Share (Quarterly)$-1.20

Price vs S&P 500 (YTD)52.39%

Gross Margin (TTM)100.00%

Net Profit Margin (TTM)-41.54%

EPS (TTM)$-1.01

10-Day Avg Trading Volume1.40M

EPS Excl Extra (TTM)$-1.01

Revenue Growth (5Y)-2.14%

EPS (Annual)$-3.16

ROI (Annual)-57.23%

Gross Margin (Annual)99.96%

Net Profit Margin (5Y Avg)-395.16%

Cash / Share (Quarterly)$3.15

Revenue Growth QoQ (YoY)19582.54%

ROA (Last FY)-43.68%

Revenue Growth TTM (YoY)1496.08%

EBITD / Share (TTM)$-0.93

ROE (5Y Avg)-15.91%

Operating Margin (TTM)-48.77%

Cash Flow / Share (Annual)$-2.84

P/B Ratio1.53x

P/B Ratio (Quarterly)1.75x

Net Income / Employee (Annual)$-1,193,400

EV / Revenue (TTM)4.03x

Net Interest Coverage (TTM)10.09x

ROA (TTM)-11.68%

EV / EBITDA (TTM)1.46x

EPS Incl Extra (Annual)$-3.16

Current Ratio (Annual)5.54x

Quick Ratio (Quarterly)5.69x

3-Month Avg Trading Volume1.77M

52-Week Price Return116.38%

EV / Free Cash Flow (Annual)-2.40x

Revenue / Employee (TTM)$826,300

Tangible BV / Share (Quarterly)$5.76

P/S Ratio (Annual)21.90x

Asset Turnover (Annual)0.07x

52-Week High$11.66

Operating Margin (5Y Avg)-438.90%

EPS Excl Extra (Annual)$-3.16

CapEx CAGR (5Y)-5.76%

Tangible BV CAGR (5Y)2.09%

26-Week Price Return26.56%

Quick Ratio (Annual)5.09x

13-Week Price Return9.75%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)6.04x

Enterprise Value$1.22B

Revenue / Share Growth (5Y)-5.04%

Asset Turnover (TTM)0.28x

Book Value / Share Growth (5Y)-0.50%

Revenue / Employee (Annual)$186,800

Pretax Margin (Annual)-638.56%

Cash / Share (Annual)$3.35

3-Month Return Std Dev49.16%

Gross Margin (5Y Avg)96.11%

Net Income / Employee (TTM)$-343,300

EBITDA Interim CAGR (5Y)4.16%

ROE (Last FY)-57.23%

Net Interest Coverage (Annual)11.83x

EPS Basic Excl Extra (Annual)$-3.16

P/FCF (TTM)12.18x

Receivables Turnover (TTM)4.18x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.01

Receivables Turnover (Annual)4.18x

ROI (TTM)-14.86%

P/S Ratio (TTM)4.95x

Pretax Margin (5Y Avg)-395.11%

Revenue / Share (Annual)$0.49

Tangible BV / Share (Annual)$5.43

Price vs S&P 500 (52W)98.06%

Year-to-Date Return64.34%

5-Day Price Return4.43%

EPS Normalized (Annual)$-3.16

ROA (5Y Avg)-13.52%

Net Profit Margin (Annual)-638.87%

Month-to-Date Return14.43%

Cash Flow / Share (TTM)$-4.36

EBITD / Share (Annual)$-3.46

Operating Margin (Annual)-699.18%

ROI (5Y Avg)-15.91%

EPS Basic Excl Extra (TTM)$-1.01

P/TBV (Quarterly)1.76x

P/B Ratio (Annual)1.10x

Pretax Margin (TTM)-41.47%

Book Value / Share (Annual)$5.49

Price vs S&P 500 (13W)6.95%

Beta1.60x

P/FCF (Annual)0.94x

Revenue / Share (TTM)$1.80

ROE (TTM)-14.86%

52-Week Low$4.35

vGradeB

gGradeB

mGradeB

vgmGradeB

VIR Earnings Surprise History

Q2 25-0.80est. -0.72

Q3 25-1.17est. -0.86

Q4 25-0.31est. -0.45

Q1 26-0.85est. 0.48

Q2 260.47est. 0.90

VIR Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.21

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	C	$14.56

About Vir Biotechnology, Inc. Common Stock

Vir Biotechnology is a clinical-stage biopharmaceutical company developing immunology-focused medicines for serious infectious diseases and cancer. The company leverages proprietary technologies including antibody engineering, an AI discovery platform (dAIsY), and a masking platform (PRO-XTEN) to develop a pipeline that includes therapies for hepatitis delta virus and HIV, as well as multiple solid tumor programs. Currently, the company generates revenue primarily through licensing agreements and research grants while advancing its clinical development programs.